192 related articles for article (PubMed ID: 20978501)
1. Immunomodulation with dendritic cells and donor lymphocyte infusion converge to induce graft vs neuroblastoma reactions without GVHD after allogeneic bone marrow transplantation.
Ash S; Stein J; Askenasy N; Yaniv I
Br J Cancer; 2010 Nov; 103(10):1597-605. PubMed ID: 20978501
[TBL] [Abstract][Full Text] [Related]
2. Early immunisation with dendritic cells after allogeneic bone marrow transplantation elicits graft vs tumour reactivity.
Gigi V; Stein J; Askenasy N; Yaniv I; Ash S
Br J Cancer; 2013 Mar; 108(5):1092-9. PubMed ID: 23511628
[TBL] [Abstract][Full Text] [Related]
3. Reconstructing immunity after allogeneic transplantation.
Giver CR; Li JM; Hossain MS; Lonial S; Waller EK
Immunol Res; 2004; 29(1-3):269-82. PubMed ID: 15181288
[TBL] [Abstract][Full Text] [Related]
4. Graft versus neuroblastoma reaction is efficiently elicited by allogeneic bone marrow transplantation through cytolytic activity in the absence of GVHD.
Ash S; Gigi V; Askenasy N; Fabian I; Stein J; Yaniv I
Cancer Immunol Immunother; 2009 Dec; 58(12):2073-84. PubMed ID: 19437016
[TBL] [Abstract][Full Text] [Related]
5. Adult thymus transplantation with allogeneic intra-bone marrow-bone marrow transplantation from same donor induces high thymopoiesis, mild graft-versus-host reaction and strong graft-versus-tumour effects.
Miyake T; Hosaka N; Cui W; Nishida T; Takaki T; Inaba M; Kamiyama Y; Ikehara S
Immunology; 2009 Apr; 126(4):552-64. PubMed ID: 18778285
[TBL] [Abstract][Full Text] [Related]
6. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
[TBL] [Abstract][Full Text] [Related]
7. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
8. Partial T cell-depleted allogeneic stem cell transplantation following reduced-intensity conditioning creates a platform for immunotherapy with donor lymphocyte infusion and recipient dendritic cell vaccination in multiple myeloma.
Levenga H; Schaap N; Maas F; Esendam B; Fredrix H; Greupink-Draaisma A; de Witte T; Dolstra H; Raymakers R
Biol Blood Marrow Transplant; 2010 Mar; 16(3):320-32. PubMed ID: 19835972
[TBL] [Abstract][Full Text] [Related]
9. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease.
Anderson LD; Mori S; Mann S; Savary CA; Mullen CA
Cancer Res; 2000 Oct; 60(20):5797-802. PubMed ID: 11059776
[TBL] [Abstract][Full Text] [Related]
10. Ex vivo fludarabine exposure inhibits graft-versus-host activity of allogeneic T cells while preserving graft-versus-leukemia effects.
Giver CR; Montes RO; Mittelstaedt S; Li JM; Jaye DL; Lonial S; Boyer MW; Waller EK
Biol Blood Marrow Transplant; 2003 Oct; 9(10):616-32. PubMed ID: 14569558
[TBL] [Abstract][Full Text] [Related]
11. T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Webb I; Doss D; Mauch P; Marcus K; Fisher D; Freeman A; Parikh B; Gribben J; Soiffer R; Ritz J; Anderson K
Blood; 2001 Aug; 98(4):934-9. PubMed ID: 11493435
[TBL] [Abstract][Full Text] [Related]
12. Cellular tumor vaccines administered after T cell-depleted allogeneic bone marrow transplantation induce effective anti-tumor immune responses.
Mundhada S; Shaw J; Mori S; Savary CA; Mullen CA
Leuk Lymphoma; 2005 Apr; 46(4):571-80. PubMed ID: 16019486
[TBL] [Abstract][Full Text] [Related]
13. Bone marrow deficient in IFN-{gamma} signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect.
Capitini CM; Herby S; Milliron M; Anver MR; Mackall CL; Fry TJ
Blood; 2009 May; 113(20):5002-9. PubMed ID: 19258593
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for malignant tumors using combination of allogeneic intra-bone marrow-bone marrow transplantation, donor lymphocyte infusion and dendritic cells.
Mukaide H; Adachi Y; Koike-Kiriyama N; Suzuki Y; Minamino K; Iwasaki M; Tsuda M; Nakano K; Koike Y; Shigematsu A; Kamiyama Y; Ikehara S
Int J Oncol; 2007 Jun; 30(6):1309-15. PubMed ID: 17487350
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Recipient leukocyte infusion enhances the local and systemic graft-versus-neuroblastoma effect of allogeneic bone marrow transplantation in mice.
Willems L; Fevery S; Sprangers B; Rutgeerts O; Lenaerts C; Ibrahimi A; Gijsbers R; Van Gool S; Waer M; Billiau AD
Cancer Immunol Immunother; 2013 Nov; 62(11):1733-44. PubMed ID: 24081484
[TBL] [Abstract][Full Text] [Related]
17. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
19. Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras.
Xia G; Truitt RL; Johnson BD
Biol Blood Marrow Transplant; 2006 Apr; 12(4):397-407. PubMed ID: 16545723
[TBL] [Abstract][Full Text] [Related]
20. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
